Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danggui Sini granules to prevent oxaliplatin-induced peripheral neurotoxicity
ChiCTR2000040536Phase 3Not yet recruiting
- Sponsor
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine
- Start
- Dec 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peripheral neuropathy comparing Oxaliplatin chemotherapy + Danggui Sini granules with Oxaliplatin chemotherapy + placebo (2 arms). Primary endpoint: NCI-CTCAE v4.0 neurotoxicity grade. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
danggui sini
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on ChiCTR2000040536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040536.